Sequence-Specific RNA Cleavage for mRNA End Quality Analysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for analyzing the 5' cap structure and 3' terminal region of mRNA are not applicable to a wide range of mRNA products, are not cost-effective, and do not allow for simultaneous analysis of both regions, leading to potential issues in mRNA quality control for therapeutic applications.

Innovation Solution

A method involving conjugates with oligonucleotides and chemical moieties with RNA cleaving activity is used to sequence-specifically cleave mRNA, allowing for the analysis of 5' and 3' fragments through hybridization and subsequent analysis by HPLC and mass spectrometry.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Loss of time

If conventional methods are used to analyze 5' cap structure and 3' terminal region separately, then analysis can be performed, but the process is time-consuming and not cost-effective

Engineering Contradiction:
Improveanalysis timeVSAvoidquality control efficiency
Core Design Contradiction:
Loss of timeVSProductivity

Solution Approach 1:

The patent combines the analysis of 5' cap structure and 3' terminal region into a single simultaneous assay using one conjugate that performs both functions. The conjugate contains a chemical moiety with RNA cleaving activity and an oligonucleotide that can cleave at both the 5' end (near cap structure) and 3' end (near homopolymeric tail) of the mRNA, enabling parallel analysis of both regions in one experiment rather than requiring separate assays.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The conjugate is designed with multi-functionality to perform multiple analysis tasks simultaneously. It can analyze different mRNA products with various sequences, cap structures, and tail compositions using a single reagent system. The oligonucleotide portion can hybridize to different target sequences while the chemical moiety maintains its RNA cleaving activity, making the assay universally applicable to diverse mRNA therapeutics.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Adaptability or versatility

If existing analysis methods are applied, then specific mRNA regions can be analyzed, but the methods are not applicable to a wide range of mRNA products

Engineering Contradiction:
ImprovemRNA product coverageVSAvoidquality control consistency
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The conjugate design enables universal application across different mRNA products. The oligonucleotide can be designed with complementary sequences that hybridize to various mRNA target regions, and the chemical moiety maintains consistent RNA cleaving activity regardless of the specific mRNA sequence. This allows the same assay system to reliably analyze diverse mRNA therapeutics including those with different cap structures (Cap0, Cap1), homopolymeric tails (polyA, polyC), and sequence variations.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The assay allows for parameter adjustments to accommodate different mRNA products. The oligonucleotide sequence can be modified to match different target sequences, and reaction conditions (temperature, buffer composition) can be optimized for specific mRNA characteristics. This flexibility maintains reliability across different mRNA products while expanding adaptability to new therapeutic candidates.

Inventive Principle:
Principle #35Parameter changes

3Measurement precision

If multiple separate assays are used for comprehensive mRNA analysis, then detailed quality control is achieved, but the process becomes complex and expensive

Engineering Contradiction:
Improvequality analysis detailVSAvoidassay complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent merges multiple quality control functions into a single integrated assay. Instead of performing separate assays for 5' cap analysis and 3' tail analysis, the conjugate simultaneously cleaves and enables analysis of both regions in one reaction mixture. This reduces the number of steps, reagents, and equipment needed while maintaining comprehensive quality control coverage including cap structure integrity, tail length, and sequence verification.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The single conjugate performs multiple functions that would traditionally require separate assays. It can detect cap structure presence and integrity, determine homopolymeric tail length and composition, and verify mRNA sequence accuracy all through one reagent system. This multi-functionality simplifies the overall assay protocol while providing detailed quality analysis across multiple parameters.

Inventive Principle:
Principle #6Universality (Multi-functionality)

4Ease of manufacture

If traditional RNA analysis methods are used, then analysis can be performed, but they are not cost-effective for routine quality control

Engineering Contradiction:
Improvecost-effectivenessVSAvoidquality control assurance
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The conjugate is designed as a stable, reusable reagent that can be stored and used for multiple assays. The chemical moiety with RNA cleving activity and the oligonucleotide portion are chemically stable and can be synthesized in large quantities at low cost. This eliminates the need for expensive enzymes or proteins that would require special handling and storage, making the assay cost-effective for routine quality control while maintaining reliable and consistent results across many uses.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method enables precise, efficient, and cost-effective analysis of mRNA quality, including cap structure, methylation patterns, and homopolymeric tail length and composition, suitable for various mRNA sequences, ensuring reliable production for therapeutic use.

Implementation Method 1

contacting the RNA molecule with the at least one conjugate provided in step (ii) under conditions allowing the hybridization of said oligonucleotide to said target sequence

Methodology Applied
Scientific EffectHybridization:

Implementation Method 2

cleavage of the RNA molecule by one or more conjugates comprising an oligonucleotide and a chemical moiety with RNA cleaving activity

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentEP3899034B1Methods for RNA analysis
Publication Date: 2026.03.18 CUREVAC SE
  • EP3899034B1 patent drawingFigure 1~2
  • EP3899034B1 patent drawingFigure 3A~3B
  • EP3899034B1 patent drawingFigure 4

AI summary

The present invention is concerned with methods for analyzing RNA molecules. The provided methods involve conjugates for RNA cleavage comprising a chemical moiety with RNA cleaving activity and an oligonucleotide. The oligonucleotide is designed based on a target sequence present in an RNA molecule, and the cleavage of the RNA molecule is inter alia carried out at conditions allowing the hybridization of the oligonucleotide to the target 5 sequence. Thereby, the method is easily applicable to RNA molecules of any sequence. The method further involves the analysis of the RNA fragments obtained after cleavage to obtain information on the physical properties of the RNA molecule.